Skip to main content
. Author manuscript; available in PMC: 2023 Mar 15.
Published in final edited form as: Cancer. 2021 Jun 23;127(19):3552–3565. doi: 10.1002/cncr.33745

Figure 2.

Figure 2.

A. Within SF3B1 mutated MDS, the K700E mutant group has distinct clinico-pathologic and genetic characteristics compared to non-K700E mutant MDS. SF3B1 non-K700E mutated patients (red) had a significantly higher frequency of mutations in RUNX1, and a trend to higher frequencies of mutations in SRSF2 and IDH2 genes compared to SF3B1 K700E mutated MDS patients. B, C: Distribution of alternative splicing events when comparing SF3B1 K700E vs. healthy controls (panel B) and SF3B1 non-K700E vs. healthy controls (panel C) and K700E vs. non-K700E patients (panel D).